Synergy CHC Corp

Aktienanalyse zu Synergy CHC Corp (SNYR)

$0.091

-0.061 (-67.02%)Zum Schluss

Loading chart…
Hoch
0.157
Eröffnung
0.137
Volumengewichteter Durchschnittskurs
0.11
Volumen
70.12M
Marktkap.
—
Tief
0.091
Umsatz
7.90M
EV/EBITDA, TTM
-8.03

Synergy CHC Corp. is a provider of consumer healthcare, beauty, and lifestyle products. The Company's brand portfolio includes FOCUSfactor and Flat Tummy. FOCUSfactor is a clinically studied brain health supplement and functional beverage line. Flat Tummy is a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals. It has six additional, non-core brands are Hand MD is a complete hand-care brand to help maintain clean and healthy hands while reducing the signs of aging; Perfekt Beauty is in beauty line of products for the eyes, lips, brows, cheeks and skin; Sneaky Vaunt is in lingerie brand with a line of women’s shapewear, bralettes and panties; The Queen Pegasus is in eyelash enhancement products for longer, thicker, natural lashes; Neuragen is in fast-acting topical treatments for neuropathic (nerve) pain, and UrgentRx is in line of fast-acting, portable, powdered over-the-counter medications.

synergychc.com

KI-Analyse of Synergy CHC Corp (SNYR)

Verkaufen

Synergy CHC Corp is not a good buy right now due to its poor financial performance and significant losses. The current price is $0.10, and the company reported a staggering net loss of $14.82 million in Q4 2025, which raises serious concerns about its sustainability. Additionally, the forward P/E ratio is 0.5347, indicating that the market is not optimistic about future earnings, and the stock has declined 94.65% year-to-date, reflecting a lack of investor confidence.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Synergy CHC Corp (SNYR) beträgt 1.83, verglichen mit dem 5-Jahres-Durchschnitt von 1.51.

Erwartetes KGV

Fair bewertet
5J-Durchschnitt P/E
1.51
Aktuelles P/E
1.83
Überbewertet
3.81
Unterbewertet
-0.79

Erwartetes EV/EBITDA

Unterbewertet
5J-Durchschnitt EV/EBITDA
1.43
Aktuelles EV/EBITDA
-8.03
Überbewertet
6.47
Unterbewertet
-3.62

Erwartetes KUV

Unterbewertet
5J-Durchschnitt P/S
0.34
Aktuelles P/S
0.04
Überbewertet
0.59
Unterbewertet
0.09

Event-Zeitleiste

2026-08-21 (ET)

09:00:00

Synergy CHC Receives Compliance Notice from Nasdaq

2026-05-15 (ET)

17:10:00

Synergy CHC Files to Sell 101.71M Shares of Common Stock

2026-04-01 (ET)

09:20:00

Company Q4 Revenue Falls to $6.07M

2026-01-27 (ET)

08:10:00

Synergy CHC Expands FOCUSfactor Product Line in Canada

2025-12-16 (ET)

08:10:00

Synergy CHC Appoints Pedro Colmenares as Sales & Marketing Director for Mexico & Latin America

News

SNYR FAQ – beantwortet von Alphio AI

Synergy CHC Corp. is a provider of consumer healthcare, beauty, and lifestyle products. The Company's brand portfolio includes FOCUSfactor and Flat Tummy. FOCUSfactor is a clinically studied brain health supplement and functional beverage line. Flat Tummy is a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals. It has six additional, non-core brands are Hand MD is a complete hand-care brand to help maintain clean and healthy hands while reducing the signs of aging; Perfekt Beauty is in beauty line of products for the eyes, lips, brows, cheeks and skin; Sneaky Vaunt is in lingerie brand with a line of women’s shapewear, bralettes and panties; The Queen Pegasus is in eyelash enhancement products for longer, thicker, natural lashes; Neuragen is in fast-acting topical treatments for neuropathic (nerve) pain, and UrgentRx is in line of fast-acting, portable, powdered over-the-counter medications. It operates in the Healthcare sector.

Synergy CHC Corp is not a good buy right now due to its poor financial performance and significant losses. The current price is $0.10, and the company reported a staggering net loss of $14.82 million in Q4 2025, which raises serious concerns about its sustainability. Additionally, the forward P/E ratio is 0.5347, indicating that the market is not optimistic about future earnings, and the stock has declined 94.65% year-to-date, reflecting a lack of investor confidence.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Ähnliche Artikel

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln